New date for meeting to discuss Sarepta's eteplirsen

FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet on April 25 to discuss an NDA for eteplirsen ( AVI-4658) from Sarepta Therapeutics Inc. (NASDAQ:SRPT) to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.

The meeting was originally scheduled for Jan. 22, but was postponed due to weather. ...